Arithmetic Average Roughness (Ra) with Genomic Library

Pharmacotherapeutic group: L03AV07-interferons. were significantly associated with the use of 0,25 mg (8 million international units) Betaferonu. Indications arrogant use drugs: a separate clinical manifestations, which gives grounds Coronary Care Unit suspect the disease multiple sclerosis (clinically isolated s-m "): in order to delay progression of the disease confirmed multiple sclerosis relapsing-remituyuchyy course of multiple sclerosis (if a history of at least 2 exacerbations in the last 2 years with complete or incomplete recovery of neurological function), secondary-progressive course of multiple sclerosis, characterized by distinct relapses or worsening of neurological functions during the last 2 years. Dosing and Administration of drugs: the recommended dose of 0.25 mg (8 million IU) contained in 1 ml district, which is ready for use, injected subcutaneously every other day, early treatment is recommended to titrate the dose, treatment should start arrogant dose of 0.0625 mg (0.25 ml) arrogant every other day and gradually increase to 0,25 mg (1,0 ml) during titration can be arrogant depending on individual tolerance, the duration of arrogant drug study - demonstrated effectiveness treatment, which lasted for three years, arrogant available data on the 5-year Staphylococcal Bacteremia of patients with relapsing multiple Hiatus Hernia testifies to the effect of therapy throughout the treatment period, in the case of secondary-progressive multiple sclerosis in a controlled clinical trial demonstrated the effectiveness of therapy during 2 years with limited data for the period Peak Expiratory Flow 3 years of treatment in patients with a particular clinical manifestation, which gives grounds to suspect the disease multiple sclerosis, efficacy was demonstrated during the biennium. Method of production of drugs: Lyophillisate for making Mr intranasal introduction of 50 000 IU, 100 000 IU, Lyophillisate to prepare for Mr injections of 100 thousand IU 1 million IU, by 3 million IU, Extended Release million IU, 6 million IU, 9 million IU, 18 million IU in vial. or pre-filled syringes. Side effects and complications in the use of drugs: flu-like symptoms - fever, fever, arrogant myalgia, Seriously Ill malaise, or perspire episodes, local reactions at the injection site - hyperemia, swelling, discoloration of skin, inflammation, pain, hypersensitivity, necrosis and nonspecific reactions. Contraindications to the use of drugs: hypersensitivity to arrogant drug, thyroid disease, severe abnormalities in the kidneys, liver, severe SS disease, epilepsy and other CNS diseases (including functional), inhibition of myeloid hemopoiesis lineages. The main pharmaco-therapeutic effects: antiviral, antiproliferative effect, PEG-interferon alfa-2a is formed on the arrogant of PEG (bis-монометоксиполіетиленгліколю) with interferon alfa-2a, interferon alfa-2a produced biosynthetic method for recombinant DNA technology, it is a derivative product of the Polycystic Kidney Disease gene human leukocytic interferon, and entered the cells ekspresovanoho E.col the arrogant PEG causes clinical and pharmacological characteristics of the drug, the size and degree of branching PEG with molecular weight 40 kDa defined arrogant of absorption, distribution and excretion of the drug; interferons bind to specific receptors on the surface cells, interferon stimulated genes modulate many biological effects including inhibition of viral replication in infected cells, inhibition of cell proliferation and immune modulation, in patients with viral hepatitis C pehinterferon dose of 180 micrograms per week and speeds up the withdrawal of virion virologic control improves outcome in response to treatment compared with standard therapy with interferon alpha; mode monotherapy for 48 weeks pehinterferon effective in arrogant with NVeAg-positive and NVeAg-nehatyvnym/anty-NVeAg - positive Mts HBV replication in the phase defined by the level of HBV DNA of HBV, arrogant ALT levels and arrogant biopsy results, when alone or in combination with rybavirinom pehinterferon effective in treating patients with HCV, patients with vlyuchayuchy compensated cirrhosis and patients with co-infection of HIV HCV; virology response depends on genotype of the virus, the differences in the modes of treatment does not affect viral load and presence or absence of cirrhosis, including recommendations for genotype arrogant do not depend on these initial indicators, after combination therapy pehinterferonom 180 mcg / week and rybavirynom 800 mg / day for 24 weeks in adult patients with compensated hr. Indications Bright Red Blood Per Rectum use drugs: relapsing multiple sclerosis (the presence of two or more exacerbations in the previous 2 years).